Methadone vs Suboxone. Why We Use Methadone

Medication-assisted treatment is the use of medication alongside therapy to manage opioid use disorder. The term covers a lot of ground. It stretches from a few days of detox support to years of maintenance, and the drugs used, the length of the course and the goal all change with the country and the treating team. Knowing what it means here, before you get on a plane, is what stops the first morning being a shock.

At Jintara the decision about which medication to use, if any, sits with the attending psychiatrist in the first hours after admission. The shape of it is a conversation between a doctor and a person, which Jintara's founder states directly, not a default prescription handed over at the desk.

The evidence for using medication during acute withdrawal is strong. NIDA's opioid research overview reports that opioid use disorder responds to medication, counselling and social support in combination, and that withdrawal managed with medication is safer and more tolerable than going without it for most people.

Three medications carry most of the weight in opioid treatment internationally. They are methadone, buprenorphine and naltrexone, and they are not interchangeable.

Methadone is a long-acting opioid agonist. Inside a controlled taper it holds withdrawal in a range a person can actually sit with, while the shorter-acting opioid clears. Buprenorphine is usually combined with naloxone and sold as Suboxone. It is a partial agonist with a ceiling effect, so past a certain dose it stops adding effect, which is what makes it a steady medication to stay on for months. Naltrexone is an opioid antagonist. It blocks the effect of opioids and belongs after detox as a relapse prevention tool, never during it.

What any given medically supervised detox can actually put in your hand depends on local law and supply, not only on the evidence base.

NIDA's research report on medications for opioid use disorder sets out the case for using these medications alongside counselling, measured on retention in treatment, reduced illicit use and overdose prevention.

Buprenorphine and Suboxone cannot legally be prescribed for addiction treatment in Thailand. That is a national regulatory position, not a gap in Jintara's formulary, and no private facility here works around it.

So if you arrive holding a Suboxone script from the UK, the United States or Australia, that script stops at the door. The clinical team tapers you off buprenorphine as part of admission rather than continuing a medication it is not legal to supply. The first methadone dose is timed so leftover buprenorphine does not collide with it, a precipitated-withdrawal risk that SAMHSA TIP 63 flags when opioid agonists are stacked. For anyone coming out of a system where buprenorphine maintenance is standard and unremarkable, this is the single most important thing to know before booking.

Methadone is legal here and Jintara uses it. Naltrexone is not part of the treatment model here, and naltrexone implants are not used. Nobody should meet that fact for the first time on arrival, which is why the first week of treatment opens with a plain conversation about what your detox is going to look like.

Methadone vs Suboxone is not a brand pick at Jintara. Methadone is a full opioid agonist. Buprenorphine, the opioid in Suboxone, is a partial one. That single difference shapes the whole withdrawal curve, which is why the taper here uses methadone rather than trying to copy a Suboxone plan that Thai law will not let it fill.

A full agonist keeps acting as the dose goes up, so a taper can be set high enough to hold someone steady through the worst of it and then stepped down in stages. A partial agonist has a ceiling. Past a point it stops adding effect, which makes it a stable thing to sit on for months and a blunter instrument for bringing someone down over weeks. Methadone also has a long half life, which is why the taper is counted in weeks rather than days.

That difference is the reasoning behind the taper used here, inside the opioid treatment program. The psychiatrist builds the schedule from the opioid used, the dose and how long it has been used, and Clinical Opiate Withdrawal Scale scores taken several times a day in the early phase guide each adjustment.

Head Nurse Lertkhwan Sukpia oversees medication administration throughout detox. Every score and every dose change is logged by Lertkhwan Sukpia into the nursing record, which is the same record the opioid detox protocol and the opioid medication protocol run on.

Methadone carries a stigma in some markets, particularly with UK clients who know it as the maintenance queue. What happens here is a different thing: a clinical taper of defined length, under nursing supervision, with an end date. The same shape is described in the NHS guidance on methadone, a dose reduced gradually until it is no longer needed, and it can run quicker in a residential setting than in community treatment. People who arrive sceptical often change position within a few days of feeling withdrawal without it.

Jintara does not recommend naltrexone, acamprosate or oral relapse prevention medication as part of the discharge plan.

The clinical position, stated by Denise O'Leary, is direct: "We don't recommend using substances to treat substances." That is a clinical philosophy, not a claim that those drugs fail. They work, for the right person in the right context. The position here is that the 30-day program should build the psychological tools, the relapse prevention plan and the aftercare structure that hold up without an ongoing prescription behind them. Naloxone kits are not provided at discharge.

This is particular to Jintara and it is not a global consensus, which the team says out loud rather than burying. For some people, especially those with a long history of high-dose opioid use, extended-release naltrexone or buprenorphine maintenance at home may be exactly the right aftercare. Where that is clinically indicated the team raises it honestly and asks you to take it to your GP or addiction specialist at home.

What you get instead is a relapse prevention plan built during the final weeks of treatment, an aftercare referral network, and a clinical team that is straight about what works for whom.